Explore the vast range of titles available.

There is no valid instrument to assess n-3 polyunsaturated fatty acids (n-3 PUFAs) intake in Iran. This study aims to develop a food frequency questionnaire (FFQ) that estimates the intake of n-3 PUFA and validate it in a healthy Iranian population based on the n-3 PUFA content of red blood cells (RBCs) and a 3-day food record (FR). A healthy population (n = 221) was recruited between February and July 2021. Participants completed the new FFQ and 3-day FR to evaluate the average intake of n-3 PUFAs. We used gas chromatography to assess the n-3 PUFA content of RBCs. To validate the FFQ based on FR and biomarker as references, the correlation coefficient was calculated. According to the Bland–Altman plots, a good agreement was found between the new FFQ and FR. Moreover, absolute intake values of ALA, EPA, DPA, DHA, and total n-3 PUFAs based on FFQ were positively correlated to their respective RBC membrane levels (coefficients between 0.205 and 0.508, p  < 0.005) and FR (coefficients between 0.771 and 0.827, p  < 0.001). This new FFQ is a valid instrument that can be applied to estimate the n-3 PUFA status of healthy Iranian adults.

Background In the last few years, the effects of bioactive food components have received much attention because of their beneficial effects including decreasing inflammation, scavenging free radicals, and regulating cell signaling pathways. Betanin as a potent antioxidant has been previously reported to exhibit anti diabetic effects. The present study aimed to evaluate the effects of betanin on glycemic control, lipid profile, hepatic function tests, as well as the gene expression levels of 5′ adenosine monophosphate‑activated protein kinase (AMPK), sirtuin-1 (SIRT1), and nuclear factor kappa B (NF‑κB) in streptozocin (STZ) induced diabetic rats. Methods Diabetes was induced in male Sprague–Dawley rats by intraperitoneal administration of STZ. Different doses of betanin (10, 20 and 40 mg/kg.b.w) was administered to diabetic rats for 28 days. Fasting blood glucose and serum insulin were measured. The histopathology of liver and pancreas tissue evaluated. Real-time PCR was performed to assess gene expression levels. Results Treatment of diabetic rats with betanin (10 and 20 mg/kg.b.w) reduced FBG levels compared to the control diabetic rats (P < 0.001). Betanin at the dose of 20 mg/kg.b.w was most effective in increasing serum insulin levels (P < 0.001) improving glucose tolerance test (GTT) as well as improvement in lipid profile and liver enzymes levels. According to histopathologic assay, different damages induced by STZ to liver and pancreas tissues was largely eliminated by treatment with 10 and 20 mg/kg.b.w of betanin. Betanin also significantly upregulated the AMPK and SIRT1 and downregulated the NF-κB mRNA expression compared to the diabetic control rats (P < 0.05). Conclusion Betanin could modulate AMPK/SIRT1/NF-κB signaling pathway and this may be one of its anti-diabetic molecular mechanisms.

Background Despite all the advances in our knowledge regarding obesity, our understanding of its etiology is still far from complete. This study aimed to evaluate the association of serum irisin levels with physical activity and some of the metabolic syndrome-related biomarkers among obese people with low-calorie intake and non-obese people with high-calorie intake. Methods Obese and non-obese healthy individuals with respectively low and high-calorie intakes were recruited. Irisin and other biomarkers were measured using standard biochemical methods. Participants’ physical activity was evaluated by administering the International Physical Activity Questionnaire (IPAQ). To analyze the body composition of the participants, a standard body composition device (ioi 353) was applied. Logistic regression was used to calculate the odds ratio (OR) and to examine the effect of confounders such as age, sex, genetics, and activity. Results Data from the seventy-seven participants were included in the final analysis. The mean age of the participants in the obese and non-obese groups was 38.33 ± 14.88 and 30.24 ± 13.37 years, respectively. Participants in the obese group had lower physical activity compared to the non-obese group (3395.38 ± 2801 MET-min/week vs. 6015.18 ± 3178 MET-min/week; p  < 0.001). The Irisin concentration in the obese and non-obese groups was 7.84 ± 2.49 ng/ml and 8.06 ± 1.89 ng/ml, respectively, which wasn’t significantly different ( p  = 0.66). We observed a noteworthy and favorable association between irisin concentration and total body water (TBW), lean body mass (LBM), and soft lean mass (SLM) in the non-obese group. Conclusions These data indicated that although obese participants were relatively inactive compared to non-obese individuals, circulating irisin level wasn’t significantly different between the two groups. Highlights No irisin difference between obese and non-obese groups. Physical activity unrelated to irisin levels. Positive irisin correlation with lean mass in non-obese group. Triglycerides and cholesterol lower in non-obese group. Irisin linked to TSH and glucose levels in obesity.

Colorectal cancer (CRC) is the third most common type of cancer worldwide. Red beetroot ( Beta vulgaris ) contains Betanin as its major betacyanin, possessing wide proapoptotic effects. This study aimed to investigate the anticancer and pro-papoptotic effects of beetroot hydro-alcoholic extract (BHE) and betanin, on colorectal cancer cell lines. BHE and betanin were used to treat Caco-2 and HT-29 colorectal cancer cells. MTT assay, DAPI staining, and FACS-flow cytometry tests were used to determine the half-maximal inhibitory concentration (IC50) and apoptosis-inducing evaluations. Intended genes were assessed by real-time polymerase chain reaction (RT-PCR). The IC50 for HT-29 and Caco-2 cell lines were 92 μg/mL, 107 μg/mL for BHE, and 64 μg/mL, 90 μg/mL for betanin at 48 h, respectively. BHE and betanin significantly inhibited the growth of both cancer cell lines time and dose-dependently. DAPI staining and flow cytometry results revealed significant apoptosis symptoms in treated cancerous cell lines. The expression level of proapoptotic genes (BAD, Caspase-3, Caspase-8, Caspase-9, and Fas-R) in treated HT-29 and Caco-2 cells was higher than in untreated and normal cells. In contrast, the anti-apoptotic gene (Bcl-2) was significantly downregulated. BHE and betanin effectively inhibited cancer cell proliferation and induced apoptosis via the modification of effective genes.

Objectives To examine associations between taste propensity and body mass index (BMI) in elderly individuals (≥ 60 years), compare taste propensity between obese and nonobese groups, and explore gender‐related differences to inform dietary interventions. Methods A cross‐sectional study was conducted with 231 elderly participants (aged ≥ 60 years) in Zanjan city, categorized into obese (n = 80) and nonobese (n = 151) groups. Taste propensity was assessed using a validated food frequency questionnaire (FFQ) evaluating six taste groups: sweet, salty, sour, bitter, umami, and fat. Pearson's correlation and independent samples t‐tests were used to examine relationships between BMI and taste propensity. Results Inverse correlations were observed between BMI and sweet (r = −0.172, p = 0.009), bitter (r = −0.139, p = 0.035), and umami (r = −0.168, p = 0.010) taste propensities; whereas there were positive correlations between BMI and salty (r = 0.204, p = 0.002) and fat (r = 0.167, p = 0.011) taste scores. Moreover, obese participants showed a lower propensity for sweet and umami tastes (p = 0.049; p < 0.001), but a higher propensity for salty and fat tastes (p = 0.029; p = 0.024) compared to nonobese individuals. A gender difference was observed in umami propensity among obese participants, with women showing a stronger propensity (p = 0.033). Conclusions Obesity in the elderly is associated with altered taste perception, particularly an increased propensity for salty and fatty foods and a decreased propensity for sweet and umami tastes. These findings may inform tailored dietary interventions in older adults. Obesity in older adults is associated with a lower propensity for sweet and umami tastes and a higher preference for salty and fatty foods. These taste shifts highlight the need for tailored dietary strategies to support healthier eating in aging populations.

Central obesity is an independent risk factor for coronary artery disease (CAD). It can increase cardio-metabolic risks through hypertension, hyperlipidemia and insulin resistance. Saffron and its bioactive compounds (crocin and crocetin) can modify some of metabolic disorders through multiple mechanisms. The aim of this study was to assess the efficacy of saffron and crocin on lipid profile, appetite, dietary intakes, anthropometric indices and body composition in patients with CAD. This 8 weeks randomized, double-blind, and placebo-controlled trial was conducted on 84 patients with CAD between the ages of 40 and 65 years old. Participants were randomly divided into groups to receive a daily supplement of 30 mg saffron aqueous extract (SAE) or 30 mg crocin or placebo. Appetite, dietary intake, anthropometry, body composition, biochemical analysis were assessed before and after the study. In SAE and crocin group, anthropometric and some body composition variables revealed a pattern of improvement after intervention. Decrease in body mass index (BMI), waist circumference and fat mass values in SAE group was significantly more than crocin group ( < 0.001). There was no significant difference at the end of study in lipid profile parameters. Both SAE and crocin yielded significant decrease in energy and dietary intake mean values ( < 0.001 and = 0.046), while it remained unchanged in the placebo group, also the appetite decreased significantly in SAE and crocin group ( < 0.001 and = 0.029, respectively). The results of present study regarding anti-obesity feature of SAE and crocin in patients with CAD was promising. However the SAE was better in appetite suppressing, dietary intake and central obesity reduction.

The present study was aimed to determine the residual amounts of chloramphenicol and enrofloxacin in broiler chickens muscle and liver sam-ples gathered from local markets of Tabriz City, northwestern Iran. Ninety broiler chickens carcasses were collected from different local markets of Tabriz, during July/August 2013. Random samples of thigh and breast muscle and liver were gathered and kept at -80(°)C until analyzes. The samples were then assayed using enzyme-linked immunosorbent assay (ELISA) according to the protocol of each antibiotic kit. Data were statistically analyzed using the computer program SAS 9.1. Eighty two samples (91/1 %) contained residues of enrofloxacin, alt-hough mean (±SD)of enrofloxacin concentration was lower than the European Union maximum residue limits(MRLs) value (P<0.001). Moreover, 28 (31/1 %) had detectable concentrations of chloramphenicol while it was not defined any MRLs value for chloramphenicol because its using has been forbidden in food animals. The frequency of contamination with enrofloxacin was considerable for the analyzed samples. Furthermore, the existence of chloramphenicol in almost one third of samples seems to be a public health threat due to its illegal use in food animals including poultry.

Background Continuing hyperglycemia causes and exacerbate oxidative stress. Betanin as the principal pigment of red beet root has antioxidant, anti-inflammatory, and anti-diabetic properties. The purpose of this study was to investigate the potency of betanin on antioxidant defense in STZ-induced diabetic rats’ livers. Methods STZ at a single dose of 60 mg/kg body weight was intraperitoneally injected and betanin (10, 20, and 40 mg/kg/day) was administered orally for 28 days. Malondialdehyde (MDA), total antioxidant capacity (TAC), protein carbonyl (PC) levels, and the enzyme activity of superoxide dismutase (SOD), catalases and glutathione peroxidases (GPx) were evaluated in the liver. Furthermore, gene expression of Nrf2 and mentioned antioxidant enzymes were measured by Real-time PCR. Results Betanin (10 and 20 mg/kg) significantly reduced PC levels and increased antioxidant enzyme activity in diabetic rats compared to the control diabetic group (P < 0.01). In comparison to the diabetic control group, all studied genes expression in diabetic rats were increased significantly with betanin at doses of 10 and 20 mg/kg (P < 0.02). The increase in gene expression at 20 mg/kg of betanin was significantly stronger than others (P < 0.015) except for the catalase (P = 0.201), that was almost the same. Moreover, treatment of diabetic rats with 20 mg/kg of betanin could significantly increase TAC levels (P < 0.05) and decrease MDA levels (P < 0.001) compared to diabetic control group. Conclusions Betanin could increase the antioxidant capacity of liver tissue associated with the Nrf2-mediated pathway in a dose-dependent manner.

Background: Depression and sexual problems are common in patients with coronary artery disease (CAD) and can influence their quality of life. Objectives: The aim of this study was to compare the efficacy of saffron and its main constituent, crocin, in improving mental and sexual health and ultimately quality of life in CAD patients. Methods: This double-blind, placebo-controlled, randomized clinical trial was carried out during 8 weeks in 3 groups, including 1 placebo and 2 intervention groups. The study sample included 58 CAD patients within the age range of 40 - 65 years, referred to Shahid Madani cardiovascular hospital, Tabriz, Iran, from April 2015 to November 2016. The intervention groups received saffron aqueous extract (SAE; 30 mg; n, 20) or crocin (30 mg; n, 19). All the groups completed the demographic questionnaire, Beck depression inventory-II (BDI-II), Hulbert index of sexual desire (HISD), and MacNew health-related quality of life questionnaire. Results: The BDI-II score significantly decreased in the SAE (pre- and post test scores, 26.10 ± 11.98 and 21.05 ± 9.93, respectively) and crocin (pre- and post test scores, 27.89 ± 8.46 and 22.68 ± 8.01, respectively) groups (P < 0.001). After adjustments for age, sex, and diagnosis time, similar results were obtained. There was no significant difference between the crocin and SAE groups in terms of total BDI-II score at the end of the study (P = 0.999). SAE and crocin had no significant effects on HISD scores (P = 0.148 and 0.317, respectively). However, they could significantly improve the total quality of life and its subscales (P < 0.001). Conclusions: SAE and crocin could improve depression and health-related quality of life in patients with CAD, whereas they had no significant effects on sexual desire.

Purpose This study aims to evaluate the effects of betanin on AMP-activated protein kinase (AMPK), Sirtuin1 (SIRT1) and Sirtuin6 (SIRT6) gene expression as well as the tumour necrosis factor alpha (TNF-α) and interleukin 6 (IL-6) cytokine release in peripheral blood mononuclear cells (PBMCs) of patients with coronary artery disease (CAD) and healthy controls. Design/methodology/approach PBMCs isolated from whole blood of 50 patients with CAD and 48 healthy subjects aged 45 to 60 years were treated with 10 and 20 µM of betanin for 24 h. Real-time polymerase chain reaction was performed to assess gene expression levels of AMPK, SIRT1 and SIRT6. The supernatants of the cultured cells were used to assess the IL-6 and TNF-α protein levels by ELISA. Findings Treatment with both doses of betanin significantly increased AMPK, SIRT1 and SIRT6 expression in PBMCs of CAD patients compared to control non-treated cells (p < 0.05). In PBMCs of healthy subjects, only treatment with high dose of betanin showed significant increase in AMPK (p = 0.007), SIRT1 (p = 0.013) and SIRT6 (p = 0.024) expression compared to control non-treated cells. Betanin (20 µM) also significantly decreased TNF-α and IL-6 concentrations in the culture supernatants of the CAD patients compared to control non-treated cells (p < 0.001). Originality/value Betanin could enhance AMPK, SIRT1 and SIRT6 gene expressions in PBMCs and represent a useful complementary treatment to reduce the proinflammatory status accompanied with CAD.